Overview

Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer. This study is to explore the feasibility of the SOL regimen on efficacy and tolerability on Chinese colorectal cancer patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shen Lin
Collaborators:
307 Hospital of PLA
Beijing Union Hosptial
Hebei Provincial Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
Treatments:
Leucovorin
Oxaliplatin